{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:36:06Z","timestamp":1793993766076,"version":"4.8.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurologic.theclinics.com","mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ncl.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T06:16:48Z","timestamp":1416982608000},"page":"175-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Wilson Disease and Other Neurodegenerations with Metal Accumulations"],"prefix":"10.1016","volume":"33","author":[{"given":"Petr","family":"Dusek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czlonkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2014.09.006_bib1","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/hep.22261","article-title":"Diagnosis and treatment of Wilson disease: an update","volume":"47","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ncl.2014.09.006_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jhep.2011.11.007","article-title":"EASL Clinical Practice Guidelines: Wilson's disease","volume":"56","author":"European Association for Study of Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ncl.2014.09.006_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/brain\/awt035","article-title":"A genetic study of Wilson's disease in the United Kingdom","volume":"136","author":"Coffey","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2004.07.017","article-title":"The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis","volume":"41","author":"Stapelbroek","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.ncl.2014.09.006_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1399-0004.2005.00528.x","article-title":"Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease","volume":"68","author":"Gromadzka","year":"2005","journal-title":"Clin Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mds.20671","article-title":"p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease","volume":"21","author":"Gromadzka","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1399-0004.2003.00179.x","article-title":"Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease","volume":"64","author":"Gu","year":"2003","journal-title":"Clin Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1351-5101.2003.00729.x","article-title":"A clinical and genetic study of 56 Saudi Wilson disease patients: identification of Saudi-specific mutations","volume":"11","author":"Al Jumah","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3109\/00365521.2010.492527","article-title":"High prevalence of fulminant hepatic failure among patients with mutant alleles for truncation of ATP7B in Wilson's disease","volume":"45","author":"Okada","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ncl.2014.09.006_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5114\/ninp.2013.34397","article-title":"Wilson disease - factors affecting clinical presentation","volume":"47","author":"Litwin","year":"2013","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.ncl.2014.09.006_bib11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2007.02.057","article-title":"Late-onset Wilson's disease","volume":"132","author":"Ferenci","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ncl.2014.09.006_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.20601","article-title":"Wilson disease in septuagenarian siblings: raising the bar for diagnosis","volume":"41","author":"Ala","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ncl.2014.09.006_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","article-title":"Diagnosis and phenotypic classification of Wilson disease","volume":"23","author":"Ferenci","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.ncl.2014.09.006_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2011.08.028","article-title":"Gender differences in Wilson's disease","volume":"312","author":"Litwin","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib15","first-page":"1","article-title":"Unified Wilson's disease rating scale - a proposal for the neurological scoring of Wilson's disease patients","volume":"41","author":"Czlonkowska","year":"2007","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.ncl.2014.09.006_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1745017901208010102","article-title":"Quality of life and psychiatric symptoms in Wilson's disease: the relevance of bipolar disorders","volume":"8","author":"Carta","year":"2012","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.ncl.2014.09.006_bib17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/archpsyc.1989.01810120068011","article-title":"Wilson's disease. Psychiatric symptoms in 195 cases","volume":"46","author":"Dening","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2014.09.006_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2007.09.009","article-title":"Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!","volume":"266","author":"Srinivas","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.parkreldis.2009.01.010","article-title":"Neuropsychiatric aspects of treated Wilson's disease","volume":"15","author":"Svetel","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11011-013-9378-2","article-title":"The effect of gender on brain MRI pathology in Wilson's disease","volume":"28","author":"Litwin","year":"2013","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.ncl.2014.09.006_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00588068","article-title":"Wilson's disease: MRI with clinical correlation","volume":"36","author":"Magalhaes","year":"1994","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ncl.2014.09.006_bib22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2214\/ajr.167.6.8956601","article-title":"Cranial MR imaging in Wilson's disease","volume":"167","author":"King","year":"1996","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ncl.2014.09.006_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00234-009-0536-5","article-title":"Wilson's disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI","volume":"51","author":"da Costa Mdo","year":"2009","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ncl.2014.09.006_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00589114","article-title":"Cranial MRI in Wilson's disease","volume":"32","author":"Prayer","year":"1990","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ncl.2014.09.006_bib25","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1212\/01.WNL.0000161847.46465.B9","article-title":"Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease","volume":"64","author":"Walter","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/00365520701514495","article-title":"Effect of penicillamine and zinc on iron metabolism in Wilson's disease","volume":"42","author":"Medici","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ncl.2014.09.006_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00868525","article-title":"Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate","volume":"243","author":"Czlonkowska","year":"1996","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-005-0720-4","article-title":"Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period","volume":"252","author":"Czlonkowska","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ene.12348","article-title":"D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease","volume":"21","author":"Czlonkowska","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ene.12320","article-title":"Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients","volume":"21","author":"Dziezyc","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(56)90066-3","article-title":"Penicillamine, a new oral therapy for Wilson's disease","volume":"21","author":"Walshe","year":"1956","journal-title":"Am J Med"},{"key":"10.1016\/j.ncl.2014.09.006_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0022-510X(87)90116-X","article-title":"Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients","volume":"77","author":"Hoogenraad","year":"1987","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.1987.00520170020016","article-title":"Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy","volume":"44","author":"Brewer","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/1531-8257(199907)14:4<551::AID-MDS1002>3.0.CO;2-S","article-title":"Penicillamine should not be used as initial therapy in Wilson's disease","volume":"14","author":"Brewer","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00023210-200519030-00001","article-title":"Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment","volume":"19","author":"Brewer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ncl.2014.09.006_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1039\/b901614g","article-title":"Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases","volume":"1","author":"Brewer","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.ncl.2014.09.006_bib37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/j.gastro.2010.12.034","article-title":"Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease","volume":"140","author":"Weiss","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ncl.2014.09.006_bib38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cgh.2013.03.012","article-title":"Efficacy and safety of oral chelators in treatment of patients with Wilson disease","volume":"11","author":"Weiss","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ncl.2014.09.006_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1365-2036.2009.03959.x","article-title":"Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease","volume":"29","author":"Wiggelinkhuizen","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ncl.2014.09.006_bib40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jocn.2012.02.041","article-title":"Trientine-induced neurological deterioration in a patient with Wilson's disease","volume":"20","author":"Kim","year":"2013","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ncl.2014.09.006_bib41","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.mcg.0000225670.91722.59","article-title":"Diagnosis and management of Wilson's disease: results of a single center experience","volume":"40","author":"Medici","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ncl.2014.09.006_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000355276","article-title":"Worsening of Wilson disease following penicillamine therapy","volume":"71","author":"Kalita","year":"2014","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1750-1172-9-41","article-title":"Zinc monotherapy is effective in Wilson's disease patients with mild liver disease diagnosed in childhood: a retrospective study","volume":"9","author":"Ranucci","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ncl.2014.09.006_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mdc3.12003","article-title":"The Pragmatic Treatment of Wilson's Disease","volume":"1","author":"Aggarwal","year":"2014","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2014.09.006_bib45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/lt.20352","article-title":"Wilson's disease in children: 37-year experience and revised King's score for liver transplantation","volume":"11","author":"Dhawan","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ncl.2014.09.006_bib46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mds.21913","article-title":"Neurological presentation of Wilson's disease in a patient after liver transplantation","volume":"23","author":"Litwin","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archneur.57.3.384","article-title":"Effect of liver transplantation on neurological manifestations in Wilson disease","volume":"57","author":"Stracciari","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/ctr.12259","article-title":"Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease","volume":"27","author":"Weiss","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ncl.2014.09.006_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nyas.12437","article-title":"Clinical considerations for an effective medical therapy in Wilson's disease","volume":"1315","author":"Weiss","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/nyas.12372","article-title":"Treatment of Wilson's disease motor complications with deep brain stimulation","volume":"1315","author":"Hedera","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5114\/ninp.2013.38230","article-title":"Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report","volume":"47","author":"Litwin","year":"2013","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.ncl.2014.09.006_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2005.087262","article-title":"Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study","volume":"56","author":"Merle","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.ncl.2014.09.006_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1478-3231.2010.02354.x","article-title":"Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation","volume":"31","author":"Bruha","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.ncl.2014.09.006_bib54","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1468-1331.2009.02607.x","article-title":"Long-term outcome in Serbian patients with Wilson disease","volume":"16","author":"Svetel","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cgh.2013.09.025","article-title":"Long-term outcomes of patients with Wilson disease in a large Austrian cohort","volume":"12","author":"Beinhardt","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ncl.2014.09.006_bib56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.gene.2013.11.039","article-title":"C19orf12 mutation leads to a pallido-pyramidal syndrome","volume":"537","author":"Kruer","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ncl.2014.09.006_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2011.12.054","article-title":"Iron dysregulation in movement disorders","volume":"46","author":"Dusek","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ncl.2014.09.006_bib58","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1212\/WNL.0b013e31827e07be","article-title":"New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN","volume":"80","author":"Hogarth","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ajhg.2011.09.007","article-title":"Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation","volume":"89","author":"Hartig","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.spen.2012.03.006","article-title":"C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation","volume":"19","author":"Panteghini","year":"2012","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2008.061929","article-title":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","volume":"46","author":"Gregory","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-410502-7.00004-1","article-title":"Mitochondrial membrane protein-associated neurodegeneration (MPAN)","volume":"110","author":"Hartig","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-410502-7.00003-X","article-title":"Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes","volume":"110","author":"Kurian","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ng.2562","article-title":"De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood","volume":"45","author":"Saitsu","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib65","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/brain\/awt095","article-title":"beta-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation","volume":"136","author":"Hayflick","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib66","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.ajhg.2012.10.019","article-title":"Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA","volume":"91","author":"Haack","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-410502-7.00006-5","article-title":"Neuroferritinopathy","volume":"110","author":"Keogh","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.53.3.617","article-title":"Estimation of the gene frequency of aceruloplasminemia in Japan","volume":"53","author":"Miyajima","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-410502-7.00007-7","article-title":"Aceruloplasminemia: an update","volume":"110","author":"Kono","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib70","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1177\/0883073812458538","article-title":"Novel mutations in FA2H-associated neurodegeneration: an underrecognized condition?","volume":"28","author":"Rupps","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib71","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1440-1789.2008.00901.x","article-title":"Redox active iron accumulation in aceruloplasminemia","volume":"28","author":"Gonzalez-Cuyar","year":"2008","journal-title":"Neuropathology"},{"key":"10.1016\/j.ncl.2014.09.006_bib72","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ng571","article-title":"Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease","volume":"28","author":"Curtis","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib73","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.neurobiolaging.2010.05.009","article-title":"Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations","volume":"33","author":"Paisan-Ruiz","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.ncl.2014.09.006_bib74","first-page":"59","article-title":"Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA)","volume":"11","author":"Schneider","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.ncl.2014.09.006_bib75","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00415-012-6521-7","article-title":"C19orf12 mutations in neurodegeneration with brain iron accumulation mimicking juvenile amyotrophic lateral sclerosis","volume":"259","author":"Deschauer","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib76","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/humu.22378","article-title":"Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12","volume":"34","author":"Landoure","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ncl.2014.09.006_bib77","doi-asserted-by":"crossref","first-page":"e12897","DOI":"10.1371\/journal.pone.0012897","article-title":"Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism","volume":"5","author":"Engel","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ncl.2014.09.006_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-410502-7.00005-3","article-title":"BPAN: the only X-linked dominant NBIA disorder","volume":"110","author":"Haack","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib79","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000310985.40011.d6","article-title":"T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation","volume":"70","author":"McNeill","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000148691","article-title":"The neurological presentation of ceruloplasmin gene mutations","volume":"60","author":"McNeill","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib81","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1212\/WNL.57.12.2205","article-title":"Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation","volume":"57","author":"Miyajima","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib82","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/brain\/awl319","article-title":"Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation","volume":"130","author":"Chinnery","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib83","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10048-011-0310-9","article-title":"Neuroferritinopathy: a new inborn error of iron metabolism","volume":"13","author":"Keogh","year":"2012","journal-title":"Neurogenetics"},{"key":"10.1016\/j.ncl.2014.09.006_bib84","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1093\/brain\/awn274","article-title":"Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation","volume":"132","author":"Devos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib85","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/mds.22669","article-title":"Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC)","volume":"24","author":"Ory-Magne","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib86","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood.V86.11.4050.bloodjournal86114050","article-title":"Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the \u201cVerona mutation\u201d)","volume":"86","author":"Girelli","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ncl.2014.09.006_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajhg.2013.11.008","article-title":"Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation","volume":"94","author":"Dusi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib88","doi-asserted-by":"crossref","first-page":"48562","DOI":"10.1074\/jbc.M406649200","article-title":"The human FA2H gene encodes a fatty acid 2-hydroxylase","volume":"279","author":"Alderson","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ncl.2014.09.006_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.02.026","article-title":"A rare family with Hereditary Spastic Paraplegia Type 35 due to novel FA2H mutations: a case report with literature review","volume":"329","author":"Cao","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2014.09.006_bib90","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2169\/internalmedicine.52.0102","article-title":"Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.ncl.2014.09.006_bib91","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.2007.120568","article-title":"Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation","volume":"79","author":"Skidmore","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2014.09.006_bib92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jhep.2010.04.039","article-title":"Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation","volume":"53","author":"Finkenstedt","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ncl.2014.09.006_bib93","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.2003.030429","article-title":"Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation","volume":"53","author":"Mariani","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ncl.2014.09.006_bib94","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cge.12145","article-title":"Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms","volume":"85","author":"Rusticeanu","year":"2014","journal-title":"Clin Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib95","article-title":"Case of presymptomatic aceruloplasminemia treated with deferasirox","author":"Tai","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ncl.2014.09.006_bib96","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5581\/1516-8484.20110104","article-title":"Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases","volume":"33","author":"Roberti Mdo","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.ncl.2014.09.006_bib97","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000008091","article-title":"A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma","volume":"42","author":"Yonekawa","year":"1999","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2014.09.006_bib98","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.braindev.2007.01.001","article-title":"Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate","volume":"29","author":"Kuhn","year":"2007","journal-title":"Brain Dev"},{"key":"10.1016\/j.ncl.2014.09.006_bib99","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib100","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ncl.2014.09.006_bib101","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","article-title":"Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up","volume":"20","author":"Cossu","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-12-410502-7.00008-9","article-title":"Therapeutic advances in neurodegeneration with brain iron accumulation","volume":"110","author":"Zorzi","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib103","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awq022","article-title":"Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation","volume":"133","author":"Timmermann","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib104","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ajhg.2012.01.018","article-title":"Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man","volume":"90","author":"Tuschl","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/B978-0-12-410502-7.00013-2","article-title":"Manganese and the brain","volume":"110","author":"Tuschl","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ajhg.2012.01.017","article-title":"Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease","volume":"90","author":"Quadri","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib107","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.25390","article-title":"Phenotypic variability in a dystonia family with mutations in the manganese transporter gene","volume":"28","author":"Delnooz","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib108","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.25138","article-title":"Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder","volume":"27","author":"Stamelou","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.006_bib109","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.clineuro.2012.12.032","article-title":"Inherited manganism","volume":"115","author":"Ribeiro","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ncl.2014.09.006_bib110","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1093\/brain\/awt255","article-title":"Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification","volume":"136","author":"Nicolas","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.09.006_bib111","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1212\/WNL.0b013e31827ccf34","article-title":"Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification","volume":"80","author":"Nicolas","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib112","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/WNL.0000000000000143","article-title":"Evaluation of SLC20A2 mutations that cause idiopathic basal ganglia calcification in Japan","volume":"82","author":"Yamada","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.006_bib113","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ng.1077","article-title":"Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis","volume":"44","author":"Wang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib114","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/humu.22582","article-title":"Genetic Screening and Functional Characterization of PDGFRB Mutations Associated with Basal Ganglia Calcification of Unknown Etiology","volume":"35","author":"Sanchez-Contreras","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ncl.2014.09.006_bib115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10048-014-0404-2","article-title":"Overall mutational spectrum of SLC20A2, PDGFB and PDGFRB in idiopathic basal ganglia calcification","volume":"15","author":"Nicolas","year":"2014","journal-title":"Neurogenetics"},{"key":"10.1016\/j.ncl.2014.09.006_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2014.9","article-title":"A de novo nonsense PDGFB mutation causing idiopathic basal ganglia calcification with laryngeal dystonia","author":"Nicolas","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ncl.2014.09.006_bib117","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/B978-0-12-410502-7.00015-6","article-title":"An update on primary familial brain calcification","volume":"110","author":"Lemos","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.ncl.2014.09.006_bib118","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/ggi.12004","article-title":"High frequency of calcification in basal ganglia on brain computed tomography images in Japanese older adults","volume":"13","author":"Yamada","year":"2013","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.ncl.2014.09.006_bib119","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2005.11.033","article-title":"Brain calcifications induce neurological dysfunction that can be reversed by a bone drug","volume":"243","author":"Loeb","year":"2006","journal-title":"J Neurol Sci"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T06:20:33Z","timestamp":1598509233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861914000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0733861914000747"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2014.09.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wilson Disease and Other Neurodegenerations with Metal Accumulations","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}